🧠 What If Alzheimer’s Starts Inside Brain Cells — Before the Plaques Take Over?

For decades, Alzheimer’s disease has been strongly associated with amyloid beta plaques — sticky protein deposits that build up between neurons. This idea shaped an entire generation of drug development. But clearing plaques has not been enough to stop or reverse the disease, which suggests the real story may begin earlier and deeper inside the cell.

A new study from the University of California, Riverside, published in PNAS Nexus, proposes a different mechanism: amyloid beta may disrupt neurons by hijacking the same internal “tracks” normally used by tau, another key brain protein.

Inside neurons, microtubules act like tiny railways, helping move vital cargo through long and fragile nerve-cell branches. Tau normally stabilizes these tracks. But the researchers found that amyloid beta can bind to microtubules with roughly similar strength — meaning that, if it accumulates inside neurons, it may compete with tau and push it away from its normal job.

That could trigger a dangerous cascade: microtubules become unstable, cellular transport starts to fail, and displaced tau begins to misbehave — clumping, becoming chemically modified, and moving into parts of the neuron where it does not belong.

In this model, plaques outside cells may not be the original weapon. They may be a visible downstream sign of a much earlier intracellular failure.

Why this matters:

🔹 Amyloid beta and tau appear to compete for overlapping binding sites on microtubules
🔹 The damage may begin inside neurons, before external plaques dominate the picture
🔹 Aging-related decline in autophagy — the cell’s recycling system — could allow amyloid beta to build up internally
🔹 The model may help explain why plaque-clearing drugs have shown limited clinical impact
🔹 It points toward new strategies: protecting microtubules, supporting tau function, or improving intracellular protein cleanup

Important caveat: this is not a clinical trial and not proof that this mechanism causes Alzheimer’s in humans. It is a proposed model based on laboratory experiments — but an interesting one, because it connects two major Alzheimer’s hallmarks, amyloid beta and tau, through the same cellular structure.

More than 57 million people worldwide live with dementia, and Alzheimer’s disease accounts for the majority of cases. If this microtubule-competition model holds up, it could shift part of the field from simply removing plaques to protecting the neuron’s internal transport system before it breaks.

Maybe the real crime scene was never just between brain cells.

Maybe it was inside them all along.

Source: https://doi.org/10.1093/pnasnexus/pgag034

#Alzheimers #Neuroscience #BrainHealth #Dementia #PNASNexus #science

🧠 Scientists May Have Found a Missing Link in How Alzheimer’s Kills Brain Cells

For decades, researchers have known that toxic proteins build up in the brains of people with Alzheimer’s disease and other neurodegenerative disorders. But one key question has remained stubbornly difficult:

How exactly does that protein buildup turn into the death of neurons?

A team from King’s College London and the UK Dementia Research Institute has now identified a previously overlooked form of cell death called karyoptosis.

Unlike apoptosis — the well-known “programmed cell death” pathway — karyoptosis appears to attack the cell’s control center first: the nucleus. Under proteotoxic stress, when misfolded proteins accumulate and clump together, the nuclear structure begins to fail. The nucleus shrivels, its supporting scaffold destabilizes, and the cell eventually dies.

The researchers analyzed around 3,000 brain cells from 28 patients with either end-stage Alzheimer’s disease or frontotemporal dementia. In the frontal cortex of Alzheimer’s patients, 35% of cells showed signs of karyoptosis, compared with 15% in healthy older controls.

The key molecular switch appears to involve p38 MAP kinase and LaminB1.

LaminB1 normally helps maintain the structure of the nuclear envelope — the “scaffolding” that keeps the nucleus intact. When toxic proteins accumulate, p38 MAP kinase can destabilize LaminB1, triggering nuclear collapse. In laboratory experiments, blocking this pathway reduced markers of karyoptosis in neurons.

That does not mean scientists have found a cure for Alzheimer’s. This is still early-stage work, and the protective effect has been shown mainly in experimental models, not in living human patients.

But the shift in thinking is important.

Instead of only trying to remove toxic proteins such as amyloid or tau, future therapies might also try to protect neurons from the damage those proteins trigger. In other words: even if the toxic proteins are still there, it may be possible to interrupt the death signal before the cell is lost.

The same mechanism also appears relevant to frontotemporal dementia and ALS models, suggesting karyoptosis may be part of a broader pathway across neurodegenerative disease.

Dementia affects around 57 million people worldwide, and Alzheimer’s disease accounts for roughly 60–70% of cases. Any new route to slowing neuron loss matters — but this one is still a biological roadmap, not a treatment.

The big takeaway:

Sometimes the most important question is not only “what causes the damage?”
It is: what chain reaction does the damage trigger — and can we stop it in time?

Original paper: https://www.nature.com/articles/s41467-026-73802-w
Summary: https://www.sciencedaily.com/releases/2026/06/260626124701.htm

#Alzheimers #Neuroscience #Dementia #BrainHealth #Science